利妥昔单抗联合沙利度胺维持治疗老年弥漫大B细胞淋巴瘤的疗效评价

目的评价利妥昔单抗联合沙利度胺维持治疗老年弥漫大B细胞淋巴瘤(Diffuse large B cell lymphoma,DLBCL)的有效性及安全性。方法回顾性分析甘肃省武威肿瘤医院血液科使用R-CHOP方案化疗后完全缓解的≥60岁的DLBCL患者86例,按其治疗方案分为2组。对照组患者在完全缓解后单用利妥昔单抗维持治疗(n=43);治疗组患者应用利妥昔单抗联合沙利度胺方案维持治疗(n=43例)。对两组患者的预后进行分析。结果治疗组4年、5年总生存期(OS)率高于对照组(P<0.01);3年、4年、5年无进展生存期(PFS)率高于对照组(P<0.01);治疗组总生存时间、无进展生存时间明显长于对照组(P<0.001)。结论利妥昔单抗联合沙利度胺维持治疗老年人DLBCL,可延长患者总生存时间及无进展生存时间,无严重不良反应发生。

Evaluation of therapeutic effect of maintenance therapy for elderly patients with diffuse large B-cell lymphoma by rituximab combined with thalidomide

Objective To evaluate the efficacy and safety of rituximab combined with thalidomide in maintenance therapy for elderly patients with diffuse large B cell lymphoma(DLBCL).Methods A total of 86 DLBCL patients aged more than 60 years,who had complete remission after R-CHOP chemotherapy in the Department of Hematology,Wuwei Cancer Hospital,Gansu Province,were retrospectively analyzed,and they were divided into two groups according to their treatment regimens.Patients in the control group were given maintenance therapy with rituximab after complete remission(n=43);patients in the treatment group were given maintenance therapy with rituximab plus thalidomide regimen(n=43).The prognosis of patients in the two groups was compared.Results The 4-year and 5-year OS rates were higher in patients receiving rituximab plus thalidomide maintenance therapy than in patients receiving rituximab maintenance therapy(P<0.01);the 3-year,4-year,and 5-year PFS rates were higher in patients receiving rituximab plus thalidomide maintenance therapy than in patients receiving rituximab maintenance therapy(P<0.01);the overall survival time and progression-free survival time were significantly longer in patients receiving rituximab plus thalidomide maintenance therapy than in patients receiving rituximab maintenance therapy(P<0.001).Conclusion Rituximab combined with thalidomide maintenance therapy for elderly patients with DLBCL can prolong the overall survival time and progression-free survival time without serious adverse reactions.